CORPORATE GOVERNANCE MMI is guided by a group of investors and professionals with years of experience in bringing new medical devices to the market. After initial funding rounds from Sambatech Angel Investors, in 2018 Medical Microinstruments S.p.A raised €20M in Series A funding to advance its robotic platform for microsurgery. The investor syndicate was led by Andera Partners, with Panakes Partners and Fountain Healthcare, returning Seed investor Sambatech, and two industry veterans from world leading companies in surgical robotics and peripheral nerve repair. ANDREW CLEELAND CHAIRMAN OF THE BOARD Andrew is a seasoned executive with over 30 years of experience in the medical device industry in both the private and public sectors. Mr. Cleeland is currently CEO of the Fogarty Institute for Innovation, a leading US non-profit incubator helping early-stage companies transform ideas into medical products that improve care. Prior to joining the Fogarty Institute, he was Vice President and General Manager of Medtronic’s (MDT:NYSE) Transcatheter Mitral Valve business following its 2015 acquisition of Twelve Inc., where he was President and CEO. Prior to Twelve, he was President and CEO of Ardian Inc., the pioneer of renal denervation for hypertension, heart failure and other associated disorders, which was also acquired by Medtronic in 2011. Together these two acquisitions totaled $1.5B. Andrew began his career with the Australian Therapeutic Goods Administration, progressed to large med tech companies in Telectronics Pacing Systems and Baxter Healthcare (BAX:NYSE), then onto the Silicon Valley start-up space working with Radiant Medical, Ardian and Twelve. He is currently Vice Chairman of The Foundry, the premier medical device incubator based in Menlo Park, California and serves as a Director on the Boards of two venture-funded companies; Saluda Medical and Zenflow, Inc. (Chairman of the Board). He was also a Director at nVision Medical that was recently acquired by Boston Scientific (BSX:NYSE). MARK TOLAND CEO Mark Toland is the CEO of MMI SpA. Before joining MMI, Mark served as the President and CEO of Corindus where he transformed the company into the industry leader in vascular robotics with the only approved system for coronary, peripheral and neurovascular indications. The Siemens Healthineers acquisition of Corindus for $1.1 billion was the fifth largest medical technology acquisition of 2019. Prior to Corindus, Mark served as Senior Vice President of Boston Scientific, where he built the company’s global solutions business and led all aspects of the U.S. commercial team’s cardiovascular businesses, which represented approximately $4 billion in revenue. Mark brings over 25 years of medical device experience to MMI. In addition, he serves on the Board of Directors for Cardiologs, a cardiovascular AI company, and Amplitude Vascular Systems, an Intravascular Lithotripsy company. He also serves as a partner and EIR at Biostar Capital, a healthcare focused Venture Capital firm. Mr. Toland holds a Bachelor of Science in Business Administration from the University of Louisville. GIUSEPPE PRISCO, PH.D. BOARD MEMBER REPRESENTING FOUNDERS Giuseppe M. Prisco is one of the co-founders of MMI S.p.A and CEO from 2015 to 2020. Before starting the company, he spent 10 years as the Managing Principal and Principal Engineer at Intuitive Surgical in California. In this role he lead several development projects including the ISI flexible robotics program. He invented, and brought to market, the daVinci Single Site product offering for single port surgery. In addition, Giuseppe has 15 years of experience as an individual technical contributor to numerous robotic products such as the 6 axis Adept Robot and the da Vinci Classic S and Si surgical robots. He is listed as the inventor on over 100 patents in controls, robotics, endoscopy and surgery. Mr. Prisco holds a degree in Computer Engineering and a Ph.D. in Robotics and Controls from the Scuola Superiore ‘Sant’ Anna’ di Studi Universitari e di Perfezionamento. ALESSIO BEVERINA BOARD MEMBER REPRESENTING PANAKES Mr. Alessio Beverina is a co-founder and General Partner of Panakes Partners, a venture capital (VC) firm headquartered in Milan, Italy. Alessio’s VC experience was developed while working at Sofinnova Partners, one of the largest VC’s in Europe where he progressed from an Analyst to a Partner. His experience included both European and American exposure. Mr. Beverina has a Master’s of Science in Chemical Engineering from Politecnico di Milano and an MBA from ESCP-EAP. In addition, Alessio is a Kauffman Fellow. OLIVIER LITZKA BOARD MEMBER REPRESENTING ANDERA PARTNERS Olivier is a partner at Andera Partners' life sciences franchise constituted by its BioDiscovery funds. Andera Partners, formerly EdRIP, Edmond de Rothschild Investment Partners, is a leading European Private Equity House, managing more than €2B in Life Sciences Venture Capital, Growth Capital, LBO, and Sponsorless Mezzanine. The team manages around €700M of assets. Previously he was a Partner at EdRIP in the Life Science fund franchise BioDiscovery, based in Paris and investing in Europe and in the US. He also worked at 3i Group PLC where he focused purely on investments in biotechnology, biopharma, medtech and healthcare companies. In addition, he represents Andera on several boards. JUSTIN LYNCH BOARD MEMBER REPRESENTING FOUNTAIN HEALTHCARE Justin Lynch is a partner in Fountain Healthcare Partners and serves as the CFO of the firm. He joined the team prior to the launch of Fund I in 2008. Justin has a particular interest in the medical device sector and led the firm's investments in MMI S.p.A., Vivasure Medical, Neuravi (acquired by J&J, 2017) and Neurent Medical. He has over 25 years of experience in capital markets, corporate finance, and entrepreneurial and venture investing across multiple sectors, particularly focused on life sciences. Justin has a Bachelor’s degree in Accounting & Finance from Dublin City University, an MBA from Trinity College Dublin and is a member of the Chartered Institute of Management Accountants. PAOLO GIUSEPPE EMILIO ALTAMURA BOARD MEMBER REPRESENTING ANGEL INVESTORS Paolo Altamura is a Founding and Managing Partner of Studio Colombo Altamura Pometto where he is responsible for International Taxation, Extraordinary Transactions and Tax Litigation matters. Mr. Altamura is registered as a Chartered Accountant and Auditor and is an expert in banking, financial taxation, managing NPLs and the associated financial instruments, with particular focus on origination, structuring and execution processes of securitization transactions. Paolo is a co-founder of several companies including: VICS Consulting S.r.l., a spin-off company of Scuola Superiore Sant'Anna in Pisa where he serves as a Director; Project Value S.r.l., a company specialized in the management of non-performing loans and in the valuation of assets underlying real estate; and Iconomics S.r.l., a consulting company, specialized in economic valuation matters and in the performance of a wide range of activities and projects in which financial analyses, evaluations and quantitative activities play a key role. Mr. Altamnura is also a Member of the Board of Statutory Auditors and Board of Directors of major industrial, commercial and financial companies and is a Member of the "FOR" Foundation. In addition, he serves as a Specialized Advisor in national and international Club Deal and Merger & Acquisition operations and has authored several articles and presented at numerous conferences. He holds a Degree in Economics at the Università Cattolica del Sacro Cuore of Milan as well as a Master's Degrees in International Taxation, Transfer Pricing and Tax Litigation, with particular reference to the application of European Union and international law. JOHN ENGELS INDEPENDENT BOARD MEMBER John Engels is a founder and investor focused on new technology development and commercialization. John co-founded AxoGen (NASDAQ:AXGN, Russell 2000), a leading medical technology company dedicated to peripheral nerve repair. John started his career at CACM, a boutique investment banking firm. In addition to MMI, John is a Board member of BioFlorida, the voice of Florida’s life sciences industry; and Oxicool, a privately-held company providing disruptive cooling technologies. John is on the advisory board of ECM Therapeutics, providing regenerative medicine through natural biomaterials; and UF Innovate, supporting an innovation ecosystem at the Univeristy of Florida. He holds a MBA in Management and Operations from the Wharton School of Business at the University of Pennsylvania, and a BA in Political Science from the University of Chicago. GUS CASTELLO INDEPENDENT BOARD MEMBER Since 2014, Gus Castello has successfully provided leadership and consulting services to small medical device companies for developing infrastructure and talent during moments of explosive new product growth. Mr. Castello has 30 years of experience in Product Operations for multi-national, medical device companies bringing disruptive technologies to the dental, orthodontics, and conventional and robotic assisted laparoscopy industries including: Sybron Dental Specialties 1995-1991 (acquired by Danaher), United States Surgical Corporation 1992-2002 (acquired by Medtronic), and most recently, Intuitive Surgical, Inc. 2002-2014. Previously, Gus was the Manufacturing Engineering Manager at Sybron (inventors of the first commercially available invisible orthodontic brace), the GM for Caribbean Operations at United States Surgical Corporation (creators of the first successful laparoscopic stapling technology), and SVP of Product Operations at Intuitive Surgical, Inc. (creators of world’s most successful laparoscopic surgical robot, the da Vinci Surgical system). Gus graduated from California State University in Long Beach with a Bachelor’s degree in Mechanical Engineer. PRIVACY POLICY MMI SPA, VIA DEL PADULETTO 10A, CALCI - PISA-, ITALIA +39 0506394MARKETING@MMIMICRO.COM Copyright 2005-2021 MMI S.p.A., all rights reserved.